Prevalence of anemia and iron deficiency in Romanian patients with inflammatory bowel disease: A prospective multicenter study

Journal of Gastrointestinal and Liver Diseases

Volumn 24, Issue 1, 2015, Pages 15-20

  Lupu, Alexandru ^a   Diculescu, Mircea ^a   Diaconescu, Razvan ^b   Tantau, Marcel ^c   Tantau, Alina ^d   Visovan, Ioana ^c   Gheorghe, Cristian ^a   Lupei, Cristina ^a   Gheorghe, Liana ^a   Cerban, Razvan ^a   Vadan, Roxana ^a   Goldis, Adrian ^b  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b Gastroenterology and Hepatology Hospital   (Romania)

^c REGIONAL INSTITUTE OF GASTROENTEROLOGY AND HEPATOLOGY   (Romania)

^d IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Anemia; Inflammatory bowel disease; Iron deficiency

Indexed keywords

ANTIANEMIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; CYANOCOBALAMIN; FERRITIN; FOLIC ACID; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ADULT; ANEMIA; ARTICLE; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CYANOCOBALAMIN DEFICIENCY; DISEASE SEVERITY; FEMALE; FOLIC ACID DEFICIENCY; HUMAN; INFLAMMATORY BOWEL DISEASE; IRON BLOOD LEVEL; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT REFERRAL; PREVALENCE; PROSPECTIVE STUDY; ROMANIA; ULCERATIVE COLITIS; ANEMIA, IRON-DEFICIENCY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COLITIS, ULCERATIVE; IMMUNOLOGY; MIDDLE AGED; TIME FACTOR;

ADULT; ANEMIA, IRON-DEFICIENCY; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; ROMANIA; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924158957     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anemia, and inflammatory bowel diseases. Gut 2004; 53: 1190-1197. doi: 10. 1136/gut. 2003. 035758.
2. World Health Organization, "Iron deficiency anemia assessment, prevention and control. A guide for programme managers, " Report WHO/NHP/01. 3, World Health Organization, Geneva, Switzerland, 2011.
3. van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013; 7: 1-33. doi: 10. 1016/j. crohns. 2012. 09. 005.
4. Weiss G., Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023. doi: 10. 1056/NEJMra041809.
5. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria; 2014. Available from: http://www. r-project. org/.
6. Guagnozzi D, Severi C, Ialongo P, et al. Ferritin as a simple indicator of iron deficiency in anemic IBD patients. Inflamm Bowel Dis 2006; 12: 150-151. doi: 10. 1097/01. MIB. 0000199223. 27595. e3.
7. Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis 2014; 20: 936-945. doi: 10. 1097/01. MIB. 0000442728. 74340. fd.
8. Alvarenga Antunes CV, Hallack Neto AA, Alvarenga Nascimento CR, et al. Anemia in inflammatory bowel disease outpatients: prevalence, risk factors, and etiology. BioMed Research International. Hindawi Publ Corp, article ID 728925, 12 Nov 2014.
9. Dumitrescu G, Dranga M, Pintilie IA, Nedelciuc O, Mihai C, Prelipcean CC. The prevalence of anaemia in patients with inflammatory bowel diseases in North-Eastern Romania. Rev Med Chir Soc Med Nat Iasi 2012; 116: 968-974.
10. Bager P, Befrits R, Wikman O, et al. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scand J Gastroenterol 2011; 46: 304-309. doi: 10. 3109/00365521. 2010. 533382.
11. Kulnigg S, Teischinger L, Dejaco C, Waldhor T, Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009; 104: 1460-1467; doi: 10. 1038/ajg. 2009. 114.
12. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-1826. doi: 10. 1053/j. gastro. 2010. 11. 058.
13. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflam Bowel Dis 2006; 12: 123-130. doi: 10. 1097/01. MIB. 0000196646. 64615. db.
14. Goddard AF, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. British Society of Gastroenterology. Gut 2000; 46 (Suppl 3-4): IV1-5. doi: 10. 1136/gut. 46. suppl_4. iv1.
15. Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008; 103: 1299-1307. doi: 10. 1111/j. 1572-0241. 2008. 01846. x.
16. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1545-1553. doi: 10. 1002/ibd. 20285.
17. Reinisch W, Chowers Y, Danese S, et al. The management of iron deficiency in inflammatory bowel disease-an online tool developed by the RAND/UCLA appropriateness method. Aliment Pharmacol Ther 2013; 38: 1109-1118. doi: 10. 1111/apt. 12493.
18. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 599-610. doi: 10. 1038/nrgastro. 2010. 151.
19. Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anemia and restoring iron stores in IBD patients: A randomised, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009; 44: 838-845. doi: 10. 1080/00365520902839667.
20. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-1192. doi: 10. 1111/j. 1572-0241. 2007. 01744. x.
21. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008; 168: 2377-2381. doi: 10. 1001/archinte. 168. 21. 2377.
22. Chen W, Lee S, Colby J, et al. The Impact of Pre-Transplant Red Blood Cell Transfusions in Renal Allograft Rejection. Rockville (MD): Agency for Healthcare Research and Quality (US): 2012, Mar 7., Report no: RENT0610.
23. Harvey AR, Basavaraju SV, Chung CW, Kuehnert MJ. Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. Transfusion 2014. doi: 10. 1111/trf. 12918.
24. Minhas V, Wood C. Epidemiology and transmission of Kaposi's sarcoma-associated herpes virus. Viruses 2014; 6: 4178-4194. doi: 10. 3390/v6114178.